Martha Stewart Insider Trading Case: What Really Happened

The Martha Stewart insider trading case is one of the most widely known securities scandals in American history — not because of the size of the trade, but because of who was involved. Stewart's sale of 3,928 shares of ImClone Systems on December 27, 2001 saved her approximately $45,673. That modest sum would ultimately cost her far more: a criminal conviction, five months in federal prison, and hundreds of millions in damage to her brand.

ImClone and the Erbitux FDA Rejection

ImClone Systems was a biotechnology company whose flagship product, Erbitux, was a promising cancer treatment. In late 2001, ImClone had submitted Erbitux for FDA approval and Wall Street was optimistic. ImClone's CEO, Sam Waksal, was a charismatic figure who had attracted a circle of high-profile investors and friends — including Martha Stewart.

On December 26, 2001, Waksal learned that the FDA was about to reject ImClone's application for Erbitux. The rejection, announced on December 28, would send ImClone's stock plummeting. Waksal immediately attempted to sell his own shares and tipped off family members to sell theirs. He was later sentenced to over seven years in prison for securities fraud, conspiracy, and perjury.

The Tip and the Trade

Martha Stewart shared a stockbroker with Waksal — Peter Bacanovic at Merrill Lynch. On December 27, 2001, while Stewart was traveling to a vacation in Mexico, Bacanovic's assistant, Douglas Faneuil, called Stewart and informed her that Waksal and his family were selling their ImClone shares.

Stewart immediately ordered the sale of all 3,928 of her ImClone shares at approximately $58 per share, receiving about $228,000. When ImClone's stock dropped to around $46 after the FDA rejection was announced the following day, Stewart had avoided a loss of roughly $45,673.

For a woman whose net worth was estimated at nearly $1 billion at the time, the amount was inconsequential. But the circumstances — a sale triggered by non-public information about an FDA decision, passed through a chain of tippers — made it a textbook case of illegal insider trading.

The Cover-Up: Where Things Got Worse

What transformed a minor stock sale into a major criminal case was the cover-up. When questioned by the SEC and FBI in early 2002, Stewart and Bacanovic claimed that they had a pre-existing agreement to sell ImClone if it fell below $60 per share. This "stop-loss" story was fabricated.

The evidence against the cover-up was substantial:

• Douglas Faneuil, the Merrill Lynch assistant, cooperated with prosecutors and testified that Bacanovic instructed him to tip Stewart about the Waksal sales.
• Phone records showed the sequence of calls: Bacanovic's office called Stewart, and Stewart immediately called back to place the sell order.
• Bacanovic had altered his personal worksheet to add a "@60" notation next to Stewart's ImClone holding, an apparent attempt to create evidence of the fake stop-loss agreement.
• An ink analysis by the Secret Service crime lab found that the "@60" notation was written with a different pen than the rest of the document.

Obstruction Charges, Not Insider Trading

In a twist that surprised many observers, Stewart was never actually charged with insider trading. Instead, the federal indictment in June 2003 charged her with:

• Conspiracy to obstruct justice and make false statements
• Obstruction of justice related to the SEC investigation
• Making false statements to federal investigators
• Securities fraud (this count was later dismissed by the judge before the case went to the jury)

Prosecutors chose this approach because the obstruction case was cleaner and easier to prove. The penalties for obstruction were severe enough, and the evidence of false statements was compelling. Stewart was convicted on all four remaining counts on March 5, 2004.

Sentencing and Prison

On July 16, 2004, Martha Stewart was sentenced to five months in federal prison, five months of home confinement, and two years of supervised probation. She was also fined $30,000. Peter Bacanovic received the same sentence.

Stewart reported to the Federal Prison Camp in Alderson, West Virginia in October 2004. She served her five months and was released in March 2005 to begin home confinement at her estate in Bedford, New York.

In a separate civil action, the SEC required Stewart to pay $195,081 — consisting of disgorgement of the $45,673 loss avoided, a civil penalty of three times that amount, and prejudgment interest. While the financial penalties were modest, the reputational damage was enormous. Martha Stewart Living Omnimedia's stock had plunged during the investigation, wiping out hundreds of millions in shareholder value.

The Comeback and Lasting Lessons

Remarkably, Stewart staged a significant comeback after her release. She returned to television, rebuilt her brand, and Martha Stewart Living Omnimedia was eventually acquired by Sequential Brands Group in 2015. Stewart remained a cultural figure, and her story became — paradoxically — a lesson in both the consequences of securities fraud and the possibility of reinvention.

The case offers several enduring lessons for investors and corporate insiders:

• The cover-up is often worse than the crime. Had Stewart simply cooperated with investigators, the outcome might have been very different. Her false statements turned a civil matter into a criminal one.
• No trade is too small to prosecute. The $45,673 loss avoided was trivial for Stewart, but the SEC and DOJ pursued the case aggressively because of its public visibility.
• Tips through intermediaries still count. Stewart didn't hear from Waksal directly — the information passed through a broker. The chain of tipping doesn't insulate recipients from liability.
• Proper trading plans matter. If Stewart had maintained a legitimate 10b5-1 trading plan, the trade would have had a legal defense.

The Martha Stewart case remains a cautionary tale about how quickly a minor lapse in judgment can escalate into a full-blown criminal prosecution — and why the systems of insider trading disclosure and enforcement exist to protect market integrity.